This report was recently updated on October 23 2024 with the latest and most recent
market numbers
Global Cystic Fibrosis Therapeutics Market Size, Trends & Analysis - Forecasts to 2026 By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration (Oral drugs, Inhaled drugs), By Region (North America, Asia Pacific, CSA, Europe, and The Middle East and Africa); End-User, Landscape, Company Market Share Analysis, and Competitor Analysis
Mucoviscidosis often referred to as cystic fibrosis, is a hereditary condition that is characterized by improper sodium and chloride transport through an epithelium, resulting in a lung infection that impairs breathing. Cystic fibrosis makes serious harm to the respiratory and stomach system. Cystic fibrosis influences the cells that produce sweat, bodily fluid, and stomach-related proteins. Ordinarily, these emitted liquids are slight and smooth like olive oil. They grease up different organs and tissues, keeping them from getting excessively dry or infected. In individuals with cystic fibrosis, be that as it may, a broken quality makes the liquids thick and tacky. Rather than going about as an oil, the liquids obstruct the pipes, cylinders, and ways in the body. This can cause the failure of the respiratory system and can also lead to malnutrition.
The disease has no permanent cure but the symptoms and complications can be reduced by early diagnosis and proper treatment. Few treatments can be used for treating cystic fibrosis such as Airway clearance techniques which clears the mucous out of the lungs and respiratory tract of the patient. Antibiotics are given on regular basis to reduce the severity of the disease. Patients are also kept on medicines such as ibuprofen as a painkiller and azithromycin for reducing the infections.
The total number of cystic fibrosis patients across the globe is 70000 with 30000 alone in the United States of America. More than 1000 new cases are detected every year in the USA. The average age for detection of two-third of the cases of cystic fibrosis is 2 years with more than 50 percent of the population who have active cystic fibrosis cases areabove 18 years of age.
The cost of the treatment for Cystic Fibrosis in a year is approximately USD 15000 and if the person is having serious issues which require much more serious treatment and will be on treatment for the rest of his/her life will be USD 3,10,000. The average cost for medicines for mild Cystic Fibrosisis 130 dollars a month. All these costs will depend on the place or country of treatment, the type of hospital that the patient is being treated, the quality of the treatment, the medical insurance terms and conditions varying concerning various medical insurance companies.
The factors driving the growth of this market are increasing number of patients suffering from the respiratory system or lung diseases along with the growth in the number of tuberculosis, pneumonia, fungal infection, and measles that increase the possibility of cystic fibrosis in patients. Moreover, cystic fibrosis is becoming more prevalent, resulting in increased awareness, strong pipeline prospects, technological improvements, and expanding R&D initiatives.The current condition of Covid – 19 pandemic wherein the patients suffering from any kind of lung diseases will be prone to infecting with Coronavirus and hence pharmaceutical and research organizations across the world are working on making new and efficient drugs. Also, due to the increasing number of respiratory diseases, market players have boosted up their production. The factor acting as a restraint to the market is the high cost of the treatment due to which every individual cannot avail of the treatment.
North America is dominating this market owing to the best facilities of healthcare systems in the region. The Asia Pacific isthe next in line and also the fastest-growing market for the forecast period.
Based on the drug class, the cystic fibrosis therapeuticsmarket can be segregated into pancreatic enzyme supplements, mucolytics, bronchodilators, and CFTR modulators.CFTR Modulators are leading the market as they are used to maintain the proper functioning of the lungs which is the most important factor in the treatment of cystic fibrosis. Currently, two CFTR modulators approved by the Food and Drug Administration (FDA) are Kalydeco and Orkambiprescribed for children having 10 different mutations of thegene that causes cystic fibrosis.This medicine is in charge of restoring the function of a protein that has been affected by the CF gene. This medication class directly treats the disease's underlying cause.
Based on the route of administration, the cystic fibrosis therapeuticsmarket can be segregated into oral drugs and inhaled drugs. Inhaled drugs segment is dominating as most of the drugs for lung diseases are available in liquid form which can be given through steamers or nebulizers. Also, medicine through the inhalation method is much more effective as they reach every pore present in every area of the lungs.
North America is dominating the market due to its bestpharmaceutical and healthcare sector in the world. Biotechnological and pharma companies in North America are working on the advancements in technology and infrastructure to increase their research work. Also, cases of various respiratory and lung disorder diseases in the region have been increasing at an alarming rate as per reports from WHO, owing to which production of drugs for lung infections have been boosted along with the research and development of new drugs.
Furthermore, Asia Pacific is projected to be the fastest-growing market in the given period due to the various technological advancements in the drug and medical sector. A growing number of asthma cases in the region is the reason for worry due to which medical councils in the region are working on vaccines and medicines that could reduce the impact of these diseases.One of the key factors expected to grow the market in the approaching years is increasing awareness among healthcare professionals and patients about advanced treatments in the market and their advantages over the present drug portfolio.
Laurent Pharmaceuticals, Spyryx Biosciences, Zambon Pharmaceuticals, AbbVie Inc., F. Hoffmann-La Roche Ltd., Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT - Advanced Inhalation Therapies, Alaxia, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc.; Alcresta Therapeutics Inc., Allergan, AstraZeneca, Translate Bio, Morphic Therapeutic, and Galecto Biotechamong others are the top players in the cystic fibrosis therapeutics market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 ReportOutlook
2.1 Global Cystic Fibrosis Therapeutics Market Overview, 2019-2026
2.1.1 IndustryOverview
2.1.2 Drug Class Overview
2.1.3 Route of Administration Overview
2.1.4 Regional Overview
Chapter 3 Global Cystic Fibrosis Therapeutics Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2019-2026
3.3 MarketKey Trends
3.3.1 Positive Trends
3.3.1.1 Increasing number of patients suffering from respiratory
system or lung diseases
3.3.1.2 Growing prevalence of cystic fibrosis
3.3.2 industry challenges
3.3.2.1 Increasing complexity of the disease
3.4 Prospective Growth Scenario
3.4.1 Drug Class
3.4.2 Route of Administration
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Technology Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Global Cystic Fibrosis Therapeutics Market, By Drug Class
4.1 Drug Class Outlook
4.2 Pancreatic Enzyme Supplements
4.2.1 Market Size, By Region, 2019-2026 (USD Million)
4.3 Mucolytics
4.3.1 Market Size, By Region, 2019-2026 (USD Million)
4.4 Bronchodilators
4.4.1 Market Size, By Region, 2019-2026 (USD Million)
4.5 CFTR Modulators
4.5.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 5 Global Cystic Fibrosis Therapeutics Market, By Route of
Administration
5.1 Route of Administration Outlook
5.2 Oral drugs
5.2.1 Market Size, By Region, 2019-2026 (USD Million)
5.3 Inhaled drugs
5.3.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 6 Global Cystic Fibrosis Therapeutics Market, By Region
6.1 Regional outlook
6.2 North America
6.2.1 Market Size, By Country 2019-2026 (USD Million)
6.2.2 Market Size, By Drug Class, 2019-2026 (USD Million)
6.2.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.2.4 U.S.
6.2.4.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.2.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.2.5 Canada
6.2.5.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.2.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3 Europe
6.3.1 Market Size, By Country 2019-2026 (USD Million)
6.3.2 Market Size, By Drug Class, 2019-2026 (USD Million)
6.3.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.4 Germany
6.3.4.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.3.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.5 UK
6.3.5.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.3.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.6 France
6.3.6.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.3.6.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.7 Italy
6.3.7.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.3.7.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.8 Spain
6.3.8.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.3.8.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.3.9 Russia
6.3.9.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.3.9.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4 Asia Pacific
6.4.1 Market Size, By Country 2019-2026 (USD Million)
6.4.2 Market Size, By Drug Class, 2019-2026 (USD Million)
6.4.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4.4 China
6.4.4.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.4.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4.5 India
6.4.5.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.4.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4.6 Japan
6.4.6.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.4.6.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.4.7 Australia
6.4.7.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.4.7.2 Market size, By Route of Administration, 2019-2026 (USD Million)
6.4.8 South Korea
6.4.8.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.4.8.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.5 Latin America
6.5.1 Market Size, By Country 2019-2026 (USD Million)
6.5.2 Market Size, By Drug Class, 2019-2026 (USD Million)
6.5.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.5.4 Brazil
6.5.4.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.5.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.5.5 Mexico
6.5.5.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.5.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.5.6 Argentina
6.5.6.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.5.6.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.6 MEA
6.6.1 Market Size, By Country 2019-2026 (USD Million)
6.6.2 Market Size, By Drug Class, 2019-2026 (USD Million)
6.6.3 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.6.4 Saudi Arabia
6.6.4.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.6.4.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.6.5 UAE
6.6.5.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.6.5.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
6.6.6 South Africa
6.6.6.1 Market Size, By Drug Class, 2019-2026 (USD Million)
6.6.6.2 Market Size, By Route of Administration, 2019-2026 (USD Million)
Chapter 7 Company Landscape
7.1 Competitive Analysis, 2020
7.2 Laurent Pharmaceuticals
7.2.1 CompanyOverview
7.2.2 Financial Analysis
7.2.3 Strategic Positioning
7.2.4 Info-Graphic Analysis
7.3 Spyryx Biosciences
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Strategic Positioning
7.3.4 Info-Graphic Analysis
7.4 Zambon Pharmaceuticals
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Strategic Positioning
7.4.4 Info-Graphic Analysis
7.5 AbbVie Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Strategic Positioning
7.5.4 Info-Graphic Analysis
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Strategic Positioning
7.6.4 Info-Graphic Analysis
7.7 Gilead
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Strategic Positioning
7.7.4 Info-Graphic Analysis
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Strategic Positioning
7.8.4 Info-Graphic Analysis
7.9 Vertex Pharmaceuticals Inc
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Strategic Positioning
7.9.4 Info-Graphic Analysis
7.10 AIT - Advanced Inhalation Therapies
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Strategic Positioning
7.10.4 Info-Graphic Analysis
7.11 Alaxia
7.11.1 Company Overview
7.11.2 Financial Analysis
7.11.3 Strategic Positioning
7.11.4 Info-Graphic Analysis
7.12 Teva Pharmaceutical Industries Ltd
7.12.1 Company Overview
7.12.2 Financial Analysis
7.12.3 Strategic Positioning
7.12.4 Info-Graphic Analysis
7.13 Merck & Co., Inc,
7.13.1 Company Overview
7.13.2 Financial Analysis
7.13.3 Strategic Positioning
7.13.4 Info-Graphic Analysis
7.14 Alcresta Therapeutics Inc.
7.14.1 Company Overview
7.14.2 Financial Analysis
7.14.3 Strategic Positioning
7.14.4 Info-Graphic Analysis
7.15 Allergan
7.15.1 Company Overview
7.15.2 Financial Analysis
7.15.3 Strategic Positioning
7.15.4 Info-Graphic Analysis
7.16 AstraZeneca
7.16.1 Company Overview
7.16.2 Financial Analysis
7.16.3 Strategic Positioning
7.16.4 Info-Graphic Analysis
7.17 Translate Bio
7.17.1 Company Overview
7.17.2 Financial Analysis
7.17.3 Strategic Positioning
7.17.4 Info-Graphic Analysis
7.18 Morphic Therapeutic
7.18.1 Company Overview
7.18.2 Financial Analysis
7.18.3 Strategic Positioning
7.18.4 Info-Graphic Analysis
7.19 Galecto Biotech
7.19.1 Company Overview
7.19.2 Financial Analysis
7.19.3 Strategic Positioning
7.19.4 Info-Graphic Analysis
7.20 Lung Therapeutics
7.20.1 Company Overview
7.20.2 Financial Analysis
7.20.3 Strategic Positioning
7.20.4 Info-Graphic Analysis
7.21 Other Companies
7.21.1 Company Overview
7.21.2 Financial Analysis
7.21.3 Strategic Positioning
7.21.4 Info-Graphic Analysis
The Global Cystic Fibrosis Therapeutics Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Cystic Fibrosis Therapeutics Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Frequently Asked Questions
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
